TY - JOUR
T1 - A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity
T2 - An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
AU - Maurea, Nicola
AU - Spallarossa, Paolo
AU - Cadeddu, Christian
AU - Madonna, Rosalinda
AU - Mele, Donato
AU - Monte, Ines
AU - Novo, Giuseppina
AU - Pagliaro, Pasquale
AU - Pepe, Alessia
AU - Tocchetti, Carlo G.
AU - Zito, Concetta
AU - Mercuro, Giuseppe
PY - 2016/5/1
Y1 - 2016/5/1
N2 - The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.
AB - The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the guidelines for a practical approach for the management of CTX in patients under anticancer target therapy.
KW - angiogenesis inhibitors
KW - HER2/epidermal growth factor receptor 2
KW - tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84970002716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84970002716&partnerID=8YFLogxK
U2 - 10.2459/JCM.0000000000000383
DO - 10.2459/JCM.0000000000000383
M3 - Article
AN - SCOPUS:84970002716
SN - 1558-2027
VL - 17
SP - S93-S104
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
ER -